Short Interest in uniQure N.V. (NASDAQ:QURE) Increases By 17.6%

uniQure N.V. (NASDAQ:QURE) saw a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 12,617,484 shares, a growth of 17.6% from the February 12th total of 10,727,684 shares. Approximately 21.2% of the shares of the company are sold short. Based on an average daily volume of 3,807,566 shares, the short-interest ratio is presently 3.3 days. Based on an average daily volume of 3,807,566 shares, the short-interest ratio is presently 3.3 days. Approximately 21.2% of the shares of the company are sold short.

uniQure Stock Up 2.6%

Shares of NASDAQ:QURE opened at $15.94 on Tuesday. The firm has a 50 day simple moving average of $21.24 and a 200 day simple moving average of $29.68. uniQure has a 52 week low of $7.76 and a 52 week high of $71.50. The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43. The company has a market cap of $996.73 million, a PE ratio of -4.62 and a beta of 0.73.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. As a group, research analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In other uniQure news, CFO Christian Klemt sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $108,720.00. Following the transaction, the chief financial officer owned 226,581 shares of the company’s stock, valued at approximately $2,052,823.86. This trade represents a 5.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 14,581 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $132,103.86. Following the completion of the sale, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at approximately $5,985,561.48. This represents a 2.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 81,399 shares of company stock worth $1,527,645 over the last ninety days. Insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of QURE. Private Trust Co. NA acquired a new stake in uniQure during the 3rd quarter worth about $28,000. Torren Management LLC purchased a new position in uniQure during the 4th quarter valued at about $28,000. Jones Financial Companies Lllp increased its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. IFP Advisors Inc purchased a new stake in shares of uniQure in the fourth quarter worth approximately $48,000. Finally, Smartleaf Asset Management LLC purchased a new stake in shares of uniQure in the fourth quarter worth approximately $48,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on QURE shares. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $15.00 to $60.00 in a research report on Monday, March 9th. Leerink Partners restated an “outperform” rating and issued a $35.00 target price on shares of uniQure in a report on Monday, March 2nd. Stifel Nicolaus set a $14.00 target price on uniQure in a research report on Monday, March 2nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.